- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02605616
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
February 28, 2024 updated by: Rita Basu, University of Alabama at Birmingham
A Randomized, Double-Blinded, Placebo-controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
We propose to evaluate hepatic fat and hepatic fibrosis using magnetic resonance elastography (MRE) liver (pre vs. post).
We will also establish glucose tolerance status by our established labeled oral glucose tolerance test (OGTT) (6,6 ²H2 glucose).
Following baseline evaluation subjects with biopsy/MRE proven NASH will be randomized to one of two groups and treated either with active drug (AZ compound) or placebo for 12 weeks (plus or minus 1 week).
Subjects with history suggestive of non-alcoholic fatty liver disease (NAFLD) or NASH will be invited to participate.
If they meet criteria following initial screening they will be included in the study.
OGTT, liver MRE will be repeated.
Liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT),alkaline phosphatase (ALP)] as well as other safety tests [creatine phosphokinase (CPK), thyroid stimulating hormone (TSH), international normalized ratio (INR),total bilirubin] will be measured before, monthly during therapy and at one month following therapy.
Furthermore, we will also do the subgroup analysis in NASH/NAFLD subjects with and without diabetes to see the effect of the drug.
Study Type
Interventional
Enrollment (Actual)
93
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Yogesh Yadav
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age: 21-75
- Body Mass Index (BMI) >19 kg/m^2
- Subjects with biopsy/MRE proven NASH [MRE liver fat ≥ 5%, with elevated liver enzymes ALT <5x upper limit normal (ULN)].
- Subjects with NAFLD and MRE shows F0 or greater fibrosis
- Subjects with history suggestive of NAFLD/NASH
- Total bilirubin must be < 1.5 x ULN and INR must be < 1.3 at baseline screening.
- TSH and CPK will be within normal limits (WNL) at screening.
- Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.
- Hemoglobin must be greater than or equal to 12.0 in males and 11.0 in females.
Exclusion Criteria:
- Medications that may affect glucose metabolism such as corticosteroids, opiates, barbiturates, and anticoagulants.
- Subjects with anemia, and symptoms suggestive of undiagnosed illness, overt hepatic disease, stroke, Alzheimer's disease, autoimmune hepatitis, alcoholism or increased alcohol consumption over the American Diabetes Association (ADA) guidelines.
- Any disorder that may potentially impact the outcome measures.
- Pregnant women and children.
- Subjects planning weight loss or in any weight loss program.
- Subjects taking TZD's, Atazanavir, Indinavir, Ketoconazole, Valproic acid, Silybum marianum and Valeriana officinalis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active drug AZ compound
AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
|
AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
|
Placebo Comparator: Placebo
Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
|
Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Hepatic Fat
Time Frame: baseline, approximately 12 weeks
|
Percentage Hepatic fat measured using Magnetic Resonance Imaging (Proton Density Fat Fraction).
A cut-off of <5% is used to distinguish between normal and fatty liver.
|
baseline, approximately 12 weeks
|
Number of Participants With no Conversion of [13C] Cortisone to [13C] Cortisol
Time Frame: baseline, approximately 12 weeks
|
Hepatic conversion of [13C] cortisone to [13C] cortisol was assessed before and after the treatment in both groups using the triple tracer cortisol test.
|
baseline, approximately 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liver Fibrosis Measured With MRE in kPa
Time Frame: baseline, approximately 12 weeks
|
Liver fibrosis will be measured with Magnetic Resonance Enterography (MRE) at baseline and then compared after ~12 weeks of treatment.
A clinical cut-off of 2.93 kPa was used to classify the results as either normal or elevated liver stiffness.
Change in Liver fibrosis (kPa) is compared in between the groups.
|
baseline, approximately 12 weeks
|
Total Insulin Sensitivity (Si) and Hepatic Insulin Sensitivity (Si Liver)
Time Frame: baseline, approximately 12 weeks
|
Total insulin sensitivity (Si) and hepatic insulin sensitivity (Si liver) will be measured with an Oral glucose Tolerance test at baseline and after ~12 weeks of treatment.
|
baseline, approximately 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Rita Basu, MD, University of Virginia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Actual)
September 1, 2019
Study Completion (Actual)
September 1, 2019
Study Registration Dates
First Submitted
September 18, 2015
First Submitted That Met QC Criteria
November 11, 2015
First Posted (Estimated)
November 16, 2015
Study Record Updates
Last Update Posted (Actual)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-000013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
No: There is not a plan to make IPD available
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-alcoholic Fatty Liver Disease (NAFLD)
-
Ann & Robert H Lurie Children's Hospital of ChicagoNot yet recruitingNAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLDUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
University of California, DavisNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
Mylan Inc.Meda Pharma S.p.A.Recruiting
-
Sohag UniversityNot yet recruitingNon-alcoholic Fatty Liver Disease NAFLD
-
Bruce A. GriffinImperial College London; University of CambridgeCompletedNon-alcoholic Fatty Liver Disease (NAFLD)United Kingdom
-
University of Southern CaliforniaWithdrawnNon-alcoholic Fatty Liver Disease (NAFLD)United States
Clinical Trials on AZ compound
-
Azafaros A.G.Active, not recruitingNiemann-Pick Disease, Type C | GM2 GangliosidosisBrazil
-
Alexza Pharmaceuticals, Inc.CelerionCompleted
-
Alexza Pharmaceuticals, Inc.CelerionCompleted
-
King Hussein Cancer CenterWithdrawn
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, GermanyActive, not recruitingSoft-tissue SarcomaUnited Kingdom
-
Arafat TfayliMerck KGaA, Darmstadt, Germany; Phoenix Clinical ResearchUnknownNon-Small Cell Lung Cancer StageLebanon, Jordan
-
Chinese PLA General HospitalCompletedBreast Neoplasms | Lung NeoplasmsChina
-
Neuromed IRCCSCompleted
-
Imperial College LondonBritish Heart FoundationRecruitingDilated CardiomyopathyUnited Kingdom
-
CeleCor TherapeuticsDiagram B.V.; ST. Antonius hospital NieuwegeinCompletedMyocardial Infarction | Heart Diseases | Vascular Diseases | Coronary Disease | STEMI - ST Elevation Myocardial InfarctionNetherlands